メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
臨床教育連携ユニット・臨床病態解析学分野
藤田医科大学
医療科学部
概要
フィンガープリント
ネットワーク
プロファイル
(2)
研究成果
(86)
フィンガープリント
臨床教育連携ユニット・臨床病態解析学分野が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Computer Assisted Tomography
100%
Magnetic Resonance Imaging
67%
Computed Tomography Angiography
54%
Brain Natriuretic Peptide
53%
Coronary Computed Tomography Angiography
47%
Heart Failure
42%
Fractional Flow Reserve
40%
Coronary Artery
31%
Revascularization
31%
Silo-Filler's Disease
30%
Heart Failure with Preserved Ejection Fraction
28%
Acute Coronary Syndrome
27%
Troponin T
26%
Cardiac Troponin
26%
Acute Kidney Injury
26%
Optical Coherence Tomography
26%
Non Small Cell Lung Cancer
26%
Positron Emission Tomography-Computed Tomography
26%
D-Dimer
26%
Disease Severity
26%
Percutaneous Coronary Intervention
26%
Intravascular Ultrasound
26%
Intensive Care Unit
26%
COVID-19
26%
Risk Stratification
23%
Lung Function
23%
Chronic Obstructive Pulmonary Disease
22%
Acute Decompensated Heart Failure
20%
Magnetic Resonance Imaging
20%
Omicron Coronavirus Variant
17%
Heart Left Ventricle Ejection Fraction
17%
Creatinine
16%
Plaque Characterization
16%
Ejection Fraction
16%
Cardiovascular System
16%
Biochemical Marker
16%
Chronic Kidney Disease
16%
Stenosis
15%
Cardiovascular Disease
15%
Statin
15%
Adverse Outcome
15%
Functional Assessment
14%
Omega-3 Fatty Acid
14%
Ground Glass Opacity
13%
Multiple Pulmonary Nodules
13%
Favipiravir
13%
Brachiocephalic Artery
13%
Acute Heart Infarction
13%
Coronary Artery Obstruction
13%
Clinical Stage
13%
Amino Terminal Sequence
13%
Lung Nodule
13%
Spiral Computed Tomography
13%
Anomalous Pulmonary Venous Connection
13%
Xenon
13%
No Reflow Phenomenon
13%
Glucose Test
13%
Body Fat
13%
Ezetimibe
13%
Radiological Finding
13%
Secondary Syphilis
13%
Syphilis
13%
Protein Z
13%
Bone Lesion
13%
Proteinuria
13%
Ischemia
13%
Urinary System
13%
Angioscopy
13%
Lung Cancer
13%
Therapy Effect
13%
Neoplasm
13%
Stent Fracture
13%
Thorax Disease
13%
Treatment Effect
13%
Functional Imaging
13%
Non-Small Cell Lung Cancer
13%
Cardiac Sarcoidosis
13%
Pentraxin 3
13%
Connective Tissue Disease
13%
Neointimal Hyperplasia
13%
Diffusion MRI
13%
Anaphylaxis
13%
Drug-Eluting Stent
13%
Icosapentaenoic Acid
13%
Radiation Pneumonia
13%
Organizing Pneumonia
13%
Smoking
13%
Moyamoya Disease
13%
Sentinel Node
13%
Fluorodeoxyglucose F 18
13%
Cancer Radiotherapy
13%
Single-Photon Emission Computed Tomography
13%
Heart Failure with Reduced Ejection Fraction
13%
Contrast Medium
13%
Carotid Artery
13%
Adipose Tissue
13%
Low Density Lipoprotein Cholesterol
13%
Lung Ventilation
13%
CHA2DS2-VASc Score
13%
Messenger RNA
13%
Keyphrases
Coronary Computed Tomography Angiography
29%
Cardiac Intensive Care Unit
26%
Computed Tomography Angiography
21%
Prognostic Value
16%
Computed Tomography
16%
Maintenance Dialysis
16%
COVID-19 Pneumonia
13%
Honeycomb Lung
13%
Sirolimus-eluting Stent
13%
Stent Fracture
13%
Innominate Artery
13%
COVID-19 Vaccine
13%
Fatty
13%
Coronary Plaque Characteristics
13%
Eicosapentaenoic Acid to Arachidonic Acid Ratio
13%
Coronary Artery Stenosis
13%
B-type Natriuretic Peptide
13%
Major Risk Factors
13%
Anomalous Pulmonary Venous Drainage
13%
Helical Computed Tomography
13%
Treatment Initiation
13%
T-type
13%
Cardiac Troponin
13%
Patients with Chronic Heart Failure
13%
Renal Angina Index
13%
Isolated Cardiac Sarcoidosis
13%
Glucose Load
13%
Urinary Liver-type Fatty Acid Binding Protein
13%
Cinderella
13%
Vitamin Deficiency
13%
Underweight Women
13%
Eicosapentaenoic Acid
13%
Prostate Brachytherapy
13%
Linked Seeds
13%
On-site Assessment
13%
Loose Seeds
13%
Angiography-derived Fractional Flow Reserve
13%
Invasive Fractional Flow Reserve
13%
Mid-term Follow-up
13%
Tumor Size
13%
Angiographic Characteristics
13%
Conference Management System
13%
Computed Tomographic
13%
Optical Coherence Tomography
13%
Angioscopy
13%
Electronic Mail
13%
IPad
13%
Acute Ischemic
13%
Contrast-induced Acute Kidney Injury (CI-AKI)
13%
Glucose Level
13%
Drug Elution
13%
Adverse Outcomes
13%
Lung Cancer
13%
Lung Texture Analysis
13%
Panel Evaluation
13%
Severity Effect
13%
Circulating Lipids
13%
Lung-RADS
13%
Acute Kidney Injury
13%
No-reflow
13%
Antithrombotic Therapy
13%
Multimarker Approach
13%
Future Hospital
13%
High-sensitivity Troponin I
13%
MRI Results
13%
Bleeding Complications
13%
Thrombotic Risk
13%
Thrombotic Events
13%
Major Bleeding
13%
Coronary Artery Stenting
13%
Failure Mode Effect Analysis
13%
Pentraxin 3 (PTX3)
13%
Intravascular Imaging
13%
CT Texture Analysis
13%
Cause-effect Analysis
13%
Primary Lung Cancer
13%
FFRCT
13%
Stable Cardiovascular Disease
13%
Single-photon Emission Computed Tomography (SPECT)
13%
Incomplete Stent Apposition
13%
Moyamoya Disease
13%
Disease Case
13%
Childhood Moyamoya
13%
System Comparison
13%
Natural History Study
13%
Preoperative Evaluation
13%
Rivaroxaban
13%
Organizing Pneumonia
13%
Tin Colloid
13%
Radiation Pneumonitis
13%
Myocardial Mass
13%
Grayscale
13%
Stable Coronary Artery Disease
13%
Safety Considerations
13%
Sentinel Node Navigation Surgery
13%
Fatty Acid Binding Protein
13%
Carotid Revascularization
13%
Radiation Safety
13%
Omicron Wave
13%
MiR-126
13%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Natriuretic Peptide
57%
Troponin T
53%
Cardiovascular Disease
47%
Heart Failure
42%
Disease
36%
Statin (Protein)
28%
Heart Failure with Preserved Ejection Fraction
28%
Acute Kidney Failure
26%
Rivaroxaban
26%
Acute Heart Failure
25%
Vaccination Policy
22%
Pitavastatin
21%
Cause of Death
20%
End Stage Renal Disease
17%
Adverse Outcome
17%
Creatinine
17%
ST Segment Elevation Myocardial Infarction
16%
Chronic Kidney Failure
16%
Receptor
15%
SARS Coronavirus
15%
Heart Infarction
14%
Acute Coronary Syndrome
14%
Heart Death
13%
Coronary Artery Disease
13%
Favipiravir
13%
Ezetimibe
13%
C Reactive Protein
13%
Immunogenicity
13%
No Reflow Phenomenon
13%
Lung Nodule
13%
Icosapentaenoic Acid
13%
Disease Severity
13%
Tablet
13%
Low Density Lipoprotein Cholesterol
13%
Fatty Acid Binding Protein
13%
Heart Ventricle Overload
13%
Immunoglobulin G Antibody
13%
Acetylsalicylic Acid
13%
Rectal Administration
13%
Iodine-123
13%
Hemoglobin A1c
13%
Antithrombotic Therapy
13%
Lung Cancer
13%
Cardiovascular Risk
13%
Pentraxin 3
13%
Anaphylaxis
13%
Hemodialysis
13%
D Dimer
13%
Underweight
13%
Vaccine
13%
Implant
13%
Lung Disease
13%
Heart Failure with Reduced Ejection Fraction
13%
Chronic Obstructive Lung Disease
13%
Contrast Medium
13%
Omega-3 Fatty Acid
13%
Radioactive Seed
13%
Warfarin
11%
Antiplatelet
11%
Coronavirinae
10%
Biological Marker
10%
Acute Heart Infarction
8%
Atenolol Plus Chlortalidone
8%
Radiation Exposure
8%
Prospective Study
8%
Stable Angina Pectoris
8%
Heart Left Ventricle Failure
6%
Cerebrovascular Disease
6%
Clinical Trial
6%
Symptom
6%
Disease Marker
6%
Brain Infarction
6%
Nitrogen 13
6%
Pathophysiology
6%
All Cause Mortality
6%
Troponin I
6%
Triacylglycerol
5%
Docosahexaenoic Acid
5%
Obesity
5%